Loading...
•
Dec 31, 2023
Aclaris Therapeutics Q4 2023 Earnings Report
Aclaris Therapeutics reported financial results for Q4 and full year 2023.
Key Takeaways
Aclaris Therapeutics reported a net loss of $1.5 million for the fourth quarter of 2023, compared to a net loss of $27.6 million for the fourth quarter of 2022. Total revenue was $17.6 million for the fourth quarter of 2023, compared to $7.8 million for the fourth quarter of 2022. As of December 31, 2023, Aclaris had aggregate cash, cash equivalents and marketable securities of $181.9 million.
Net loss was $1.5 million for the fourth quarter of 2023 compared to $27.6 million for the fourth quarter of 2022.
Total revenue was $17.6 million for the fourth quarter of 2023 compared to $7.8 million for the fourth quarter of 2022, primarily driven by a one-time upfront payment under the license agreement with Sun Pharma.
Research and development (R&D) expenses were $26.6 million for the quarter ended December 31, 2023 compared to $21.1 million for the prior year period.
As of December 31, 2023, Aclaris had aggregate cash, cash equivalents and marketable securities of $181.9 million compared to $229.8 million as of December 31, 2022.
Aclaris Therapeutics
Aclaris Therapeutics
Aclaris Therapeutics Revenue by Segment
Revenue by Segment
Contract research Revenue
CapyFin.comLicensing Revenue
CapyFin.comRevenue & Expenses
Visualization of income flow from segment revenue to net income